Gyre Therapeutics (GYRE) Cash & Equivalents (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Cash & Equivalents for 17 consecutive years, with $37.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 917.36% year-over-year to $37.5 million; the TTM figure through Mar 2026 stood at $37.5 million (up 917.36% YoY), while the FY2025 annual figure was $24.9 million, up 110.81% from the prior year.
• Cash & Equivalents advanced to $37.5 million in Q1 2026 per GYRE's latest filing, from $24.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $75.4 million in Q2 2022 and bottomed at $2.2 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $22.6 million across 5 years, with a median of $16.0 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 90.35% — and 2026, when it soared 917.36%.
• Gyre Therapeutics' Cash & Equivalents stood at $23.1 million in 2022, then tumbled by 54.17% to $10.6 million in 2023, then climbed by 11.51% to $11.8 million in 2024, then soared by 110.81% to $24.9 million in 2025, then soared by 50.75% to $37.5 million in 2026.
• Business Quant data shows GYRE's Cash & Equivalents at $37.5 million in Q1 2026, $24.9 million in Q4 2025, and $40.4 million in Q3 2025.